Business Wire

Mastercard Opens European Cyber Resilience Centre in Belgium

Share

Mastercard today announced the opening of its European Cyber Resilience Centre (ECRC) at its European Headquarters reaffirming the company’s commitment to combatting cyber threats and enhancing resilience in the region. The new state-of-the-art centre will sharpen defenses against cyber threats, speed up response times and serve as a hub for thought leadership in cybersecurity, fostering collaboration between the public and private sectors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530937171/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mastercard European Cyber Resilience Centre Opening in Waterloo, Belgium. (From left to right) Michael Miebach, Chief Executive Officer, Mastercard, Mathieu Michel, Belgian State Secretary for Digitalisation, Mark Barnett, President, Mastercard Europe, Catherine De Bolle, Executive Director, Europol. Photo by: Nicolas Peeters. (Photo: Business Wire)

With continuous digitization and unprecedented levels of connectivity, cybercrime presents a shared challenge across all organizations. Fraudsters are using technology in more innovative and sophisticated ways to try and harm consumers and businesses. Cybercrime has turned into a global economy now estimated to be worth trillions of euros.

To address this ever-evolving threat landscape, the ECRC brings together partners from across the public and private sectors. By leveraging its facilities and diverse talent pool, it facilitates collaboration with national cyber intelligence centres, law enforcement agencies, and industry bodies across Europe.

"In today’s hyperconnected world, cybercrime is evolving and so are we. This centre will bring together the brightest minds from business, government and other sectors to stay ahead of threats and make the digital world as secure as possible. Afterall, the work to ensure people can trust that they are safe online doesn’t stop at our four walls — or our firewalls," said Michael Miebach, CEO, Mastercard.

The Centre bolsters Mastercard’s ability to combat cyber threats across the digital ecosystem and helps it protect, detect, and respond to attacks. It fosters deeper connections with customers, partners, and stakeholders and drives collaboration across the region, enhancing resilience.

The Mastercard European Cyber Resilience Centre includes a Fusion Centre, the heart of Mastercard’s organizational incident response, and a Digital Forensics Lab in addition to representatives from more than 20 teams - all crucial to running an effective Resilience Centre.

"At Europol, we are strong believers that no single actor, sector or nation, can face the threats of cybercriminals alone. Each of us has a complementary role to play. By bringing together all relevant actors, the European Cyber Resilience Centre has the potential to bring excellence into our cross-sectoral collaboration," said Catherine De Bolle, Executive Director, Europol.

"It is with great pride that I am here today for the inauguration of the Mastercard European Cyber Resilience Centre. I am delighted that Belgium has been chosen to host this first centre in Europe dedicated to cybersecurity for Mastercard, and even more so because it will be established in the heart of Walloon Brabant. We live in a world where cyber threats are omnipresent and constantly evolving. Cyberattacks know no borders and affect all sectors of our society, from the public to the private sector, from critical infrastructures to ordinary citizens. It is therefore imperative that we unite to meet these challenges with determination and efficiency. This event marks a significant milestone in our shared commitment to strengthening cybersecurity in Europe and Belgium. The European Cyber Resilience Centre represents a key initiative to promote collaboration between the public and private sector, as well as regulatory bodies. By working hand in hand, we can significantly improve our ability to prevent, detect and respond to cyber threats," said Mathieu Michel, Belgian Secretary of State for Digitalization.

The commitment to European security is reflective of Mastercard's role in powering economies and empowering people. This is underscored by its robust infrastructure, which facilitated the protection of 143 billion transactions in 2023 alone. Upholding high standards of privacy, data responsibility, and cybersecurity, Mastercard continues to deliver seamless and secure transactions while safeguarding customer information.

About Mastercard (NYSE: MA), www.mastercard.com

Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments and businesses realize their greatest potential. With connections across more than 210 countries and territories, we are building a sustainable world that unlocks priceless possibilities for all.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

James Issokson, james.issokson@mastercard.com, 914-648-9971
Seth Eisen, seth.eisen@mastercard.com, 914-249-3153

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions21.6.2024 21:45:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive results in the VX-880 trial and reinforce the transformative potential of this therapy. At baseline, all patients in the study had undetectable fasting C-peptide (a marker of endogenous insulin secretion), a history of recurrent SHEs in the year prior to screening, and required an average of 39.3 (min, max; 19.8, 52.0) units of insulin per day. Following a single infusion of VX-880 at the full dose, all 12 patients demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90. At the latest visi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye